AACR 2023 Highlights Novel Research in NSCLC and ES-SCLC
Research presented at AACR 2023 highlighted a potential new standard of care for NSCLC and other novel treatments for NSCLC and ES-SCLC.
Research presented at AACR 2023 highlighted a potential new standard of care for NSCLC and other novel treatments for NSCLC and ES-SCLC.
Combining camonsertib with PARP inhibitors may be an effective strategy for treating advanced solid tumors, a study suggests.
First-line treatment with surufatinib and toripalimab provided disease control in 100% of patients with advanced, PD-L1+ NSCLC.
Salmonella-IL2 plus FOLFIRINOX may be more effective than FOLFIRINOX alone in patients with stage IV pancreatic cancer, a phase 2 study suggests.
Combination treatment with MEDI1191 and durvalumab has demonstrated activity in a phase 1 trial of patients with advanced solid tumors.
ALLO-316 has shown activity in a phase 1 study of patients with heavily pretreated, advanced clear cell renal cell carcinoma.
A bispecific CAR T-cell therapy produced responses in 91% of patients with relapsed/refractory non-Hodgkin lymphoma in a phase 1 trial.
The bispecific antibody AFM13 elicits responses in patients with relapsed/refractory peripheral T-cell lymphoma, a phase 2 study suggests.
Petosemtamab can produce durable responses in patients with advanced head and neck squamous cell carcinoma, a phase 1/2 study suggests.
Following genetic screening guidelines may cause clinicians to miss as many as 40% of patients with high-risk hereditary cancer syndromes, a study suggests.